Effect of sodium-glucose cotransporter-2 inhibitors on uric acid in patients with heart failure and preserved ejection fraction: a retrospective analysis in real word
Abstract
BACKGROUND AND AIMS: While sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are known to lower serum uric acid (SUA) in heart failure with reduced ejection fraction (HFrEF) or diabetes, their urate-lowering effect in heart failure with preserved ejection fraction (HFpEF) remains unclear. This study aimed to evaluate this effect in HFpEF patients. METHODS: HFpEF patients newly treated with SGLT-2i were retrospectively included. Changes in SUA level and gout events were analyzed during follow-up. RESULTS: We selected 734 patients according to propensity score matching, with the median age of 75.0(66.0–85.0) years. 31.9% were combined with chronic kidney disease(CKD) and the mean SUA was 6.4 ± 1.9 mg/dl. At 3 to 6-month follow-up, SGLT-2i treatment (79.6% dapagliflozin ) was associated with greater reduction of SUA (-0.91 ± 1.63 mg/dl vs. -0.10 ± 1.54 mg/dl; p < 0.001) and fasting glucose (-0.49(-1.59 to 0.37) vs. 0(-0.83 to 0.39) mmol/l, p = 0.002). 16 cases in SGLT-2i group had gout events and 23 cases in control group (p = 0.25). No significant difference was analyzed in estimated glomerular filtration rate (eGFR) change between groups. The control rate of SUA (< 6 mg/dl) was 72.2% and 51.2% respectively (p < 0.001). Multiple regression analysis suggested that changes of SUA were closely associated with gender, basal SUA level, eGFR and eGFR changes. Subgroup analysis showed that SGLT-2i could reduce SUA regardless of whether combined with diabetes or CKD, and the…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 734 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.